The US FDA issued similar warning letters to five different online peptide vendors on 24th August, giving the companies 15 ...
Custom autologous cell therapies face immense manufacturing bottlenecks, steep financial costs, and vein-to-vein logistical ...
MHRA's first two centralised programmes are focusing on software or AI used as a medical device (SaMD/AIaMD) and the use of ...
PMV Pharma is preparing to file for approval of its oral p53 protein reactivator drug rezatopopt in the first quarter of 2027 ...
The US Advanced Research Projects Agency for Health (ARPA-H) has awarded $125 million in funding, split across five groups, ...
Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in relapsing multiple sclerosis (RMS ...
Novartis has paused eight clinical trials of its experimental CAR-T therapy rapcabtagene autoleucel (rap-cel or YTB323) after ...
AstraZeneca and Daiichi Sankyo's Enhertu, given in combination with Roche's Perjeta, has become the first new frontline ...
Nine mid-sized pharma companies have signed up for the Trump administration's Most Favoured Nation (MFN) pricing deals, ...
US biotech NeOnc Technologies has applied to list on the Nasdaq as it advances a portfolio of drugs to treat diseases affecting the central nervous system. The Westlake Village, California-based ...
Roche is paying $75 million for a trispecific antibody developed by a subsidiary of China's Simcere Pharma as a treatment for ...
Takeda and Protagonist Therapeutics' hepcidin mimetic rusfertide has been approved by the FDA to treat polycythaemia vera (PV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results